Cohort characteristics by atrial fibrillation (AF) status
| Characteristic | All | Non-AF | AF |
| No of patients | 165 184 | 152 734 | 12 450 |
| Demographics | |||
| Age (years) | 55.8±12.9 | 55.2±12.8 | 63.5±11.5 |
| Female | 69 412 (42.0) | 65 459 (42.9) | 3953 (31.8) |
| (Delete this row) | |||
| Past history | |||
| Congestive heart failure | 12 540 (9.1) | 9424 (7.5) | 3116 (25.0) |
| Hypertension | 102 079 (61.8) | 91 108 (59.7) | 10 971 (88.1) |
| Diabetes | 28 178 (17.1) | 25 461 (16.7) | 2717 (21.8) |
| Cerebrovascular event | 8563 (5.2) | 7076 (4.6) | 1487 (11.9) |
| Coronary artery disease | 36 622 (22.2) | 32 120 (21) | 4502 (36.2) |
| Vascular disease | 8690 (5.3) | 7660 (5.0) | 1030 (8.3) |
| Smoking history | 80 329 (48.6) | 73 823 (48.3) | 6506 (52.3) |
| End-stage renal disease | 4346 (3.1) | 3653 (2.9) | 693 (5.6) |
| CHA2DS2-VASc score | 2.2±1.2 | 2.1±1.2 | 2.8±1.4 |
| 0–1 | 80 048 (48.4) | 77 167 (50.5) | 2881 (23.1) |
| 2 | 40 730 (24.7) | 37 552 (24.6) | 3178 (25.5) |
| 3 | 24 833 (15) | 21 895 (14.3) | 2938 (23.6) |
| 4 | 12 222 (7.4) | 10 263 (6.7) | 1959 (15.7) |
| 5–9 | 7351 (4.5) | 5857 (3.8) | 1494 (12.0) |
| Medications | |||
| Anticoagulation | 13 857 (8.4) | 7397 (4.8) | 6460 (51.9) |
| Aspirin | 60 096 (36.4) | 54 707 (35.8) | 5389 (43.3) |
| Statin use | 48 812 (29.6) | 44 296 (29.0) | 4516 (36.3) |
| Beta blocker use | 49 251 (29.8) | 42 292 (27.7) | 6959 (55.9) |
| ACEi/ARB | 47 551 (28.8) | 42 128 (27.6) | 5423 (43.6) |
| Insulin | 9343 (5.7) | 8411 (5.5) | 932 (7.5) |
| Metabolic equivalent of tasks | 9.0±2.8 | 9.1±2.7 | 7.4±2.8 |
All numbers are frequency (percentage) or mean±SD.
ACEi/ARB, ACE inhibitor/angiotensin receptor blocker.